Background/Aims: The objective of this study was to determine whether treatment with acetylcholinesterase inhibitors would provide cognitive benefit for patients with vascular dementia. Methods: Studies in patients with vascular dementia, who had not taken acetylcholinesterase inhibitors or memantine for at least 6 weeks, were included. Results: Twelve studies were included in the final analysis. Donepezil showed significant improvement in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) as compared to placebo, at the doses tested, that is, 5 and 10 mg/day (difference in means -1.389 and -1.680, respectively, p ≤ 0.008), but not on the Mini Mental State Examination (MMSE) (p ≥ 0.259). Galantamine also improved the ADAS-cog in comparison to the placebo (difference in means -2.191, p < 0.001), whereas, rivastigmine did not show any benefit on ADAS-cog. However, the findings with rivastigmine are difficult to interpret, given there were only 2 studies. Treatment with cholinesterase inhibitors was associated with a twofold increase in the odds of discontinuation, due to adverse events (pooled OR 1.966, 95% CI 1.630-2.371, p < 0.001). Conclusion: The present results reveal the therapeutic benefits of donepezil and galantamine in patients with vascular dementia. Interestingly, the ADAS-cog and MMSE varied considerably in detecting cognitive improvement.

1.
Hébert R, Brayne C: Epidemiology of vascular dementia. Neuroepidemiology 1995;14:240-257.
2.
Knopman DS, Parisi JE, Boeve BF, Cha RH, Apaydin H, Salviati A, Edland SD, Rocca WA: Vascular dementia in a population-based autopsy study. Arch Neurol 2003;60:569-575.
3.
Rocca WA, Kokmen E: Frequency and distribution of vascular dementia. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S9-S14.
4.
Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A: A population-based study of dementia in 85-year-olds. N Engl J Med 1993;328:153-158.
5.
Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ; WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and Other Dementias: World federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. World J Biol Psychiatry 2011;12:2-32.
6.
Grantham C, Geerts H: The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. J Neurol Sci 2002;203-204:131-136.
7.
Román GC, Kalaria RN: Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006;27:1769-1785.
8.
Möbius HJ, Stöffler A: Memantine in vascular dementia. Int Psychogeriatr 2003;15(suppl 1):207-213.
9.
Kavirajan H, Schneider LS: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782-792.
10.
Cummings JL: Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4-15.
11.
Burns A, O'Brien J; BAP Dementia Consensus Group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology: Clinical practice with anti-dementia drugs: a consensus statement from British association for psychopharmacology. J Psychopharmacol 2006;20:732-755.
12.
Johnson JW, Kotermanski SE: Mechanism of action of memantine. Curr Opin Pharmacol 2006;6:61-67.
13.
Birks J, Flicker L: Investigational treatment for vascular cognitive impairment. Expert Opin Investig Drugs 2007;16:647-658.
14.
van de Glind EM, van Enst WA, van Munster BC, Olde Rikkert MG, Scheltens P, Scholten RJ, Hooft L: Pharmacological treatment of dementia: a scoping review of systematic reviews. Dement Geriatr Cogn Disord 2013;36:211-228.
15.
Román GC, Salloway S, Black SE, Royall DR, Decarli C, Weiner MW, Moline M, Kumar D, Schindler R, Posner H: Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010;41:1213-1221.
16.
Narasimhalu K, Effendy S, Sim CH, Lee JM, Chen I, Hia SB, Xue HL, Corrales MP, Chang HM, Wong MC, Chen CP, Tan EK: A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurol Scand 2010;121:217-224.
17.
Erkinjuntti T, Gauthier S, Bullock R, Kurz A, Hammond G, Schwalen S, Zhu Y, Brashear R: Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). J Psychopharmacol 2008;22:761-768.
18.
Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R: Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin 2008;24:2561-2574.
19.
Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, Posner H, Chabriat HS: Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 2008;7:310-318.
20.
Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C; GAL-INT-26 Study Group: Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007;69:448-458.
21.
Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ: Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005;20:338-344.
22.
Bullock R, Erkinjuntti T, Lilienfeld S; GAL-INT-6 Study Group: Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord 2004;17:29-34.
23.
Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD; Donepezil 308 Study Group: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61:479-486.
24.
Johnson & Johnson Pharmaceutical Research and Development LLC: A Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia. https://clinicaltrials.gov/ct2/show/NCT00035191?term=nct00035191&rank=1 (accessed July 28, 2015).
25.
Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R; Donepezil 307 Vascular Dementia Study Group: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-2330.
26.
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-1290.
27.
Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. www.cochrane-handbook.org (updated March 2011).
28.
Loy C, Schneider L: Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;1:CD001747.
29.
Schneider LS: Cholinesterase inhibitors for vascular dementia? Lancet Neurol 2003;2:658-659.
30.
Lee AY: Vascular Dementia. Chonnam Med J 2011;47:66-71.
31.
Passmore AP, Bayer AJ, Steinhagen-Thiessen E: Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. J Neurol Sci 2005;229-230:141-146.
32.
Baquero M, Martín N: Depressive symptoms in neurodegenerative diseases. World J Clin Cases 2015;3:682-693.
33.
Wouters H, van Gool WA, Schmand B, Zwinderman AH, Lindeboom R: Three sides of the same coin: measuring global cognitive impairment with the MMSE, ADAS-cog and CAMCOG. Int J Geriatr Psychiatry 2010;25:770-779.
34.
Birks J, McGuinness B, Craig D: Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2013;5:CD004744.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.